

Tomas Radivoyevitch

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7037629/tomas-radivoyevitch-publications-by-citations.pdf>

Version: 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

134
papers

2,520
citations

26
h-index

47
g-index

138
ext. papers

3,249
ext. citations

5.4
avg. IF

4.82
L-index

#	Paper	IF	Citations
134	Dynamics of clonal evolution in myelodysplastic syndromes. <i>Nature Genetics</i> , 2017 , 49, 204-212	36.3	228
133	Genetic alterations of the cohesin complex genes in myeloid malignancies. <i>Blood</i> , 2014 , 124, 1790-8	2.2	151
132	Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198. <i>Cancer Research</i> , 2015 , 75, 4790-802	10.1	108
131	Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes. <i>Leukemia</i> , 2016 , 30, 2214-2220	10.7	98
130	Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy. <i>Clinical Cancer Research</i> , 2013 , 19, 938-48	12.9	96
129	The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014 , 1846, 326-41	11.2	93
128	Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis. <i>JCI Insight</i> , 2018 , 3,	9.9	85
127	Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study. <i>PLoS Medicine</i> , 2017 , 14, e1002382	11.6	80
126	IMMU-70. GLOBAL IMMUNE FINGERPRINTING IN GLIOBLASTOMA REVEALS IMMUNE-SUPPRESSION SIGNATURES ASSOCIATED WITH PROGNOSIS. <i>Neuro-Oncology</i> , 2018 , 20, vi137-vi137	11.37	78
125	Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1831-1839	2.2	67
124	Tet2 loss leads to hypermutagenicity in haematopoietic stem/progenitor cells. <i>Nature Communications</i> , 2017 , 8, 15102	17.4	61
123	Genomic determinants of chronic myelomonocytic leukemia. <i>Leukemia</i> , 2017 , 31, 2815-2823	10.7	61
122	Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates. <i>Journal of Clinical Investigation</i> , 2018 , 128, 4260-4279	15.9	61
121	Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes. <i>Journal of Clinical Investigation</i> , 2015 , 125, 1043-55	15.9	60
120	Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms. <i>Leukemia</i> , 2015 , 29, 2134-42	10.7	57
119	p53 independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia. <i>Leukemia</i> , 2011 , 25, 1739-50	10.7	57
118	Mutations Sensitize Acute Myeloid Leukemia to PARP Inhibition and This Is Reversed by IDH1/2-Mutant Inhibitors. <i>Clinical Cancer Research</i> , 2018 , 24, 1705-1715	12.9	53

117	Defining AML and MDS second cancer risk dynamics after diagnoses of first cancers treated or not with radiation. <i>Leukemia</i> , 2016 , 30, 285-94	10.7	44
116	Metronomic capecitabine as an immune modulator in glioblastoma patients reduces myeloid-derived suppressor cells. <i>JCI Insight</i> , 2019 , 4,	9.9	44
115	Clinical features and treatment outcomes in large granular lymphocytic leukemia (LGLL). <i>Leukemia and Lymphoma</i> , 2018 , 59, 416-422	1.9	42
114	p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies. <i>Seminars in Oncology</i> , 2012 , 39, 97-108	5.5	42
113	Adding molecular data to prognostic models can improve predictive power in treated patients with myelodysplastic syndromes. <i>Leukemia</i> , 2017 , 31, 2848-2850	10.7	41
112	Consequences of mutant TET2 on clonality and subclonal hierarchy. <i>Leukemia</i> , 2018 , 32, 1751-1761	10.7	30
111	Bleeding incidence and risk factors among cancer patients treated with anticoagulation. <i>American Journal of Hematology</i> , 2019 , 94, 780-785	7.1	29
110	Invariant patterns of clonal succession determine specific clinical features of myelodysplastic syndromes. <i>Nature Communications</i> , 2019 , 10, 5386	17.4	29
109	Rational management approach to pure red cell aplasia. <i>Haematologica</i> , 2018 , 103, 221-230	6.6	29
108	Runx1 regulation of Pu.1 corepressor/coactivator exchange identifies specific molecular targets for leukemia differentiation therapy. <i>Journal of Biological Chemistry</i> , 2014 , 289, 14881-95	5.4	26
107	GATA4 loss of function in liver cancer impedes precursor to hepatocyte transition. <i>Journal of Clinical Investigation</i> , 2017 , 127, 3527-3542	15.9	26
106	Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma. <i>Leukemia Research</i> , 2018 , 74, 130-136	2.7	24
105	Germline loss-of-function and alterations in adult myelodysplastic syndromes. <i>Blood</i> , 2018 , 132, 2309-2313	10.3	23
104	Sex differences in the incidence of chronic myeloid leukemia. <i>Radiation and Environmental Biophysics</i> , 2014 , 53, 55-63	2	22
103	Machine learning demonstrates that somatic mutations imprint invariant morphologic features in myelodysplastic syndromes. <i>Blood</i> , 2020 , 136, 2249-2262	2.2	21
102	Risk of developing chronic myeloid neoplasms in well-differentiated thyroid cancer patients treated with radioactive iodine. <i>Leukemia</i> , 2018 , 32, 952-959	10.7	20
101	Quantitative modeling of chronic myeloid leukemia: insights from radiobiology. <i>Blood</i> , 2012 , 119, 4363-71	12	19
100	Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network. <i>Leukemia</i> , 2021 , 35, 1023-1036	10.7	19

99	Biologically based risk estimation for radiation-induced CML. Inferences from BCR and ABL geometric distributions. <i>Radiation and Environmental Biophysics</i> , 2001 , 40, 1-9	2	18
98	Mathematical analysis of DNA fragment distribution models used with pulsed-field gel electrophoresis for DNA double-strand break calculations. <i>Electrophoresis</i> , 1996 , 17, 1087-93	3.6	18
97	Invariant phenotype and molecular association of biallelic mutant myeloid neoplasia. <i>Blood Advances</i> , 2019 , 3, 339-349	7.8	18
96	BRCC3 mutations in myeloid neoplasms. <i>Haematologica</i> , 2015 , 100, 1051-7	6.6	17
95	Methods for analysis of DNA fragment distributions on pulsed field gel electrophoretic gels. <i>Electrophoresis</i> , 1996 , 17, 1080-6	3.6	17
94	The relationship between eligibility criteria and adverse events in randomized controlled trials of hematologic malignancies. <i>Leukemia</i> , 2017 , 31, 1808-1815	10.7	16
93	A Therapeutic Strategy for Preferential Targeting of TET2 Mutant and TET-dioxygenase Deficient Cells in Myeloid Neoplasms. <i>Blood Cancer Discovery</i> , 2021 , 2, 146-161	7	15
92	Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide. <i>Leukemia</i> , 2016 , 30, 2405-2409	10.7	14
91	Molecular features of early onset adult myelodysplastic syndrome. <i>Haematologica</i> , 2017 , 102, 1028-1034	6.6	13
90	Context dependent effects of ascorbic acid treatment in TET2 mutant myeloid neoplasia. <i>Communications Biology</i> , 2020 , 3, 493	6.7	13
89	Subclonal STAT3 mutations solidify clonal dominance. <i>Blood Advances</i> , 2019 , 3, 917-921	7.8	12
88	Higher-Level Pathway Objectives of Epigenetic Therapy: A Solution to the p53 Problem in Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017 , 37, 812-824	7.1	11
87	The risk of chronic myeloid leukemia: can the dose-response curve be U-shaped?. <i>Radiation Research</i> , 2002 , 157, 106-9	3.1	11
86	The complexity of interpreting genomic data in patients with acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2016 , 6, e510	7	11
85	Modeling the low-LET dose-response of BCR-ABL formation: predicting stem cell numbers from A-bomb data. <i>Mathematical Biosciences</i> , 1999 , 162, 85-101	3.9	10
84	Genomics of therapy-related myeloid neoplasms. <i>Haematologica</i> , 2020 , 105, e98-e101	6.6	10
83	Estimating Cured Fractions of Uveal Melanoma. <i>JAMA Ophthalmology</i> , 2021 , 139, 174-181	3.9	10
82	Distinct clinical and biological implications of various DNMT3A mutations in myeloid neoplasms. <i>Leukemia</i> , 2018 , 32, 550-553	10.7	9

81	Long-Term Outcomes of Hairy Cell Leukemia Treated With Purine Analogs: A Comparison With the General Population. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017 , 17, 857-862	2	9
80	Biologically-based risk estimation for radiation-induced chronic myeloid leukemia. <i>Radiation and Environmental Biophysics</i> , 2000 , 39, 153-9	2	9
79	Modelling c-Abl Signalling in Activated Neutrophils: the Anti-inflammatory Effect of Seliciclib. <i>BioDiscovery</i> , 2013 , 7, 4		9
78	Ionizing radiation exposures in treatments of solid neoplasms are not associated with subsequent increased risks of chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2016 , 43, 9-12	2.7	9
77	The evolution of paroxysmal nocturnal haemoglobinuria depends on intensity of immunosuppressive therapy. <i>British Journal of Haematology</i> , 2018 , 182, 730-733	4.5	9
76	Extended experience with a non-cytotoxic DNMT1-targeting regimen of decitabine to treat myeloid malignancies. <i>British Journal of Haematology</i> , 2020 , 188, 924-929	4.5	8
75	Long-Term Deficits in Behavior Performances Caused by Low- and High-Linear Energy Transfer Radiation. <i>Radiation Research</i> , 2017 , 188, 672-680	3.1	7
74	A two-way interface between limited Systems Biology Markup Language and R. <i>BMC Bioinformatics</i> , 2004 , 5, 190	3.6	7
73	New drugs for pharmacological extension of replicative life span in normal and progeroid cells. <i>Npj Aging and Mechanisms of Disease</i> , 2019 , 5, 2	5.5	7
72	A novel genetic and morphologic phenotype of ARID2-mediated myelodysplasia. <i>Leukemia</i> , 2018 , 32, 839-843	10.7	7
71	Clonal PIGA mosaicism and dynamics in paroxysmal nocturnal hemoglobinuria. <i>Leukemia</i> , 2018 , 32, 2507-2511	10.7	6
70	Folate system correlations in DNA microarray data. <i>BMC Cancer</i> , 2005 , 5, 95	4.8	6
69	Estimation of the target stem-cell population size in chronic myeloid leukemogenesis. <i>Radiation and Environmental Biophysics</i> , 1999 , 38, 201-6	2	6
68	Higher-Level Pathway Objectives of Epigenetic Therapy: A Solution to the p53 Problem in Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017 , 37, 812-824	7.1	6
67	Mlh1 deficiency increases the risk of hematopoietic malignancy after simulated space radiation exposure. <i>Leukemia</i> , 2019 , 33, 1135-1147	10.7	6
66	Preclinical Modeling of Surgery and Steroid Therapy for Glioblastoma Reveals Changes in Immunophenotype that are Associated with Tumor Growth and Outcome. <i>Clinical Cancer Research</i> , 2021 , 27, 2038-2049	12.9	6
65	Impact of germline CTC1 alterations on telomere length in acquired bone marrow failure. <i>British Journal of Haematology</i> , 2019 , 185, 935-939	4.5	5
64	RE: Colorectal Cancer Incidence Patterns in the United States, 1974-2013. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.7	5

63	A mathematical model of human thymidine kinase 2 activity. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2011 , 30, 203-9	1.4	5
62	Mass action models versus the Hill model: an analysis of tetrameric human thymidine kinase 1 positive cooperativity. <i>Biology Direct</i> , 2009 , 4, 49	7.2	5
61	Time course solutions of the Sax-Markov binary rejoining/misrejoining model of DNA double-strand breaks. <i>Radiation and Environmental Biophysics</i> , 2000 , 39, 265-73	2	5
60	Distinctive and common features of moderate aplastic anaemia. <i>British Journal of Haematology</i> , 2020 , 189, 967-975	4.5	4
59	Automated mass action model space generation and analysis methods for two-reactant combinatorially complex equilibria: an analysis of ATP-induced ribonucleotide reductase R1 hexamerization data. <i>Biology Direct</i> , 2009 , 4, 50	7.2	4
58	Equilibrium model selection: dTTP induced R1 dimerization. <i>BMC Systems Biology</i> , 2008 , 2, 15	3.5	4
57	Rational polynomial representation of ribonucleotide reductase activity. <i>BMC Biochemistry</i> , 2005 , 6, 8	4.8	4
56	On target cell numbers in radiation-induced H4-RET mediated papillary thyroid cancer. <i>Radiation and Environmental Biophysics</i> , 2001 , 40, 191-7	2	4
55	The Mechanism By Which Mutant Nucleophosmin (NPM1) Creates Leukemic Self-Renewal Is Readily Reversed. <i>Blood</i> , 2016 , 128, 444-444	2.2	4
54	Conditional Survival in Uveal Melanoma. <i>Ophthalmology Retina</i> , 2021 , 5, 536-542	3.8	4
53	A pilot clinical trial of oral tetrahydrouridine/decitabine for noncytotoxic epigenetic therapy of chemoresistant lymphoid malignancies. <i>Seminars in Hematology</i> , 2021 , 58, 35-44	4	4
52	PBRM1 loss in kidney cancer unbalances the proximal tubule master transcription factor hub to repress proximal tubule differentiation. <i>Cell Reports</i> , 2021 , 36, 109747	10.6	4
51	On model ensemble analyses of nonmonotonic data. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2012 , 31, 147-56	1.4	3
50	Non-Cytotoxic Differentiation Therapy Based On Mechanism of Disease Produces Complete Remission in Myelodysplastic Syndromes (MDS) with High Risk Cytogenetics. <i>Blood</i> , 2012 , 120, 1696-1696 ²⁻²	2.2	3
49	The Revised International Prognostic Scoring System "Molecular" (IPSS-Rm), a Validated and Dynamic Model in Treated Patients with Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2015 , 126, 607-607	2.2	3
48	A pilot clinical trial of the cytidine deaminase inhibitor tetrahydrouridine combined with decitabine to target DNMT1 in advanced, chemorefractory pancreatic cancer. <i>American Journal of Cancer Research</i> , 2020 , 10, 3047-3060	4.4	3
47	Uveal melanoma: Long-term survival. <i>PLoS ONE</i> , 2021 , 16, e0250939	3.7	3
46	Machine learning integrates genomic signatures for subclassification beyond primary and secondary acute myeloid leukemia. <i>Blood</i> , 2021 , 138, 1885-1895	2.2	3

45	Protons and High-Linear Energy Transfer Radiation Induce Genetically Similar Lymphomas With High Penetrance in a Mouse Model of the Aging Human Hematopoietic System. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020 , 108, 1091-1102	4	2
44	Stochastic process pharmacodynamics: dose timing in neonatal gentamicin therapy as an example. <i>AAPS Journal</i> , 2015 , 17, 447-56	3.7	2
43	Cell of Origin Determination in Diffuse Large B-Cell Lymphoma: Performance of Immunohistochemical (IHC) Algorithms and Ability to Predict Outcome. <i>Blood</i> , 2011 , 118, 950-950	2.2	2
42	Ex Vivo Experiments Show That IDH1/2-Mutant Inhibitors Can be Safely Used As Adjuvants to Regular Chemotherapy in IDH1/2-Mutated Acute Myeloid Leukemia. <i>Blood</i> , 2015 , 126, 3788-3788	2.2	2
41	Forty-Year Analysis of Randomized Clinical Trials in Patients with Acute Myeloid Leukemia Treated with Remission Induction Chemotherapy. <i>Blood</i> , 2016 , 128, 2786-2786	2.2	2
40	Clonal Dynamics of Refractory Aplastic Anemia in Patients Treated with Eltrombopag. <i>Blood</i> , 2016 , 128, 3892-3892	2.2	2
39	Identification of gene expression determinants of radiosensitivity in bladder cancer (BC) cell lines.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e16507-e16507	2.2	2
38	Whole-Exome Sequencing Identifies Germline IDH2 and IDH3 mutations That Predispose to Myeloid Neoplasms. <i>Blood</i> , 2015 , 126, 1405-1405	2.2	2
37	Inhibition of yeast ribonucleotide reductase by Sml1 depends on the allosteric state of the enzyme. <i>FEBS Letters</i> , 2016 , 590, 1704-12	3.8	2
36	Chronic myeloid leukemia: Two mysteries. <i>Leukemia Research</i> , 2019 , 79, 3-5	2.7	1
35	5-formylcytosine and 5-hydroxymethyluracil as surrogate markers of TET2 and SF3B1 mutations in myelodysplastic syndrome, respectively. <i>Haematologica</i> , 2020 , 105, e213-e215	6.6	1
34	TET 2 Alterations in Myeloid Malignancies, Impact on Clinical Characteristics, Outcome, and Disease Predisposition. <i>Blood</i> , 2015 , 126, 1645-1645	2.2	1
33	Molecular Predictors of Response in Patients with Myeloid Neoplasms Treated with Lenalidomide. <i>Blood</i> , 2015 , 126, 2853-2853	2.2	1
32	Impact of Eltrombopag on Expansion of Clones with Somatic Mutations in Refractory Aplastic Anemia. <i>Blood</i> , 2015 , 126, 300-300	2.2	1
31	Clinical Effects of IDH1/2-Mutant Inhibitors in IDH1/2-Mutated Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients: Suggestions from Ex Vivo Experiments. <i>Blood</i> , 2016 , 128, 4308-4308	2.2	1
30	Cardiac death rates after irradiation for esophageal cancer: An epidemiologic study among esophageal cancer survivors.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4049-4049	2.2	1
29	Resistance to decitabine and 5-azacytidine emerges from adaptive responses of the pyrimidine metabolism network		1
28	Evolutionary Dynamics of Chronic Myeloid Leukemia Progression: the Progression-Inhibitory Effect of Imatinib. <i>AAPS Journal</i> , 2016 , 18, 914-22	3.7	1

27	The impact of socioeconomic disparities on the use of upfront autologous stem cell transplantation for mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2021 , 1-9	1.9	1
26	Aging effects on oxidative phosphorylation in rat adrenocortical mitochondria. <i>Mechanisms of Ageing and Development</i> , 2014 , 138, 10-4	5.6	
25	How to use the computing environment R to analyze ATP-induced ribonucleotide reductase R1 hexamerization data. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2010 , 29, 427-32	1.4	
24	The Mechanisms By Which Mutant-NPM1 Uncouples Differentiation from Proliferation Are Reversed By Several Drugs, Enabling Rational Multi-Component Non-Cytotoxic Differentiation Therapy. <i>Blood</i> , 2017 , 130, 878-878	2.2	
23	How far have we really come? Trends in survival and mortality for gliomas between 1973 to 2014 from SEER.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2038-2038	2.2	
22	Heterozygous CTC1 Variants in Acquired Bone Marrow Failure. <i>Blood</i> , 2018 , 132, 3866-3866	2.2	
21	BRCA1 & BRCA2 Germline Variants Are Enriched in MDS/AML and Portend Higher Average Mutational Burden. <i>Blood</i> , 2018 , 132, 4352-4352	2.2	
20	Biallelic TET2 Inactivation in Myeloid Neoplasia: From Clonal Hierarchy to Clinical Phenotypes. <i>Blood</i> , 2018 , 132, 1805-1805	2.2	
19	Survival Outcomes of Patients with Therapy-Related Myelodysplastic Syndromes in the United States. <i>Blood</i> , 2018 , 132, 371-371	2.2	
18	Identification of gene expression determinants of radiosensitivity in bladder cancer (BCa) cell lines.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 470-470	2.2	
17	Determinants of Phenotypic Commitment and Clonal Progression--Conclusions from the Study of Clonal Architecture in CMML. <i>Blood</i> , 2015 , 126, 2848-2848	2.2	
16	Radioactive Iodine Treatment of Thyroid Cancer and Risk of Myelodysplastic Syndromes. <i>Blood</i> , 2015 , 126, 612-612	2.2	
15	Eligibility Criteria Are Not Associated with Expected or Observed Adverse Events in Randomized Controlled Trials (RCTs) of Hematologic Malignancies. <i>Blood</i> , 2015 , 126, 635-635	2.2	
14	Characterization of the Mutational Spectrum in Young Patients with Myelodysplastic Syndrome. <i>Blood</i> , 2015 , 126, 5218-5218	2.2	
13	The Complexity of Interpreting Genomic Data in Patients with Primary and Secondary Acute Myeloid Leukemia (AML). <i>Blood</i> , 2015 , 126, 86-86	2.2	
12	Thirty-year analysis of randomized clinical trials in patients with acute myeloid leukemia.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 7032-7032	2.2	
11	Evolving Risk of Myelodysplastic Syndromes Among Adolescents and Young Adults Following Radiation Treatment for First Cancers in the United States, 1973 - 2014. <i>Blood</i> , 2016 , 128, 4334-4334	2.2	
10	Response-Adapted Therapy for Newly Diagnosed Myeloma. <i>Blood</i> , 2016 , 128, 3606-3606	2.2	

- 9 UTX mutations in Myeloid Neoplasms. *Blood*, **2016**, 128, 3148-3148 2.2
- 8 Landscape of Subclonal Mutations in Myelodysplastic Syndromes (MDS) Allows for a Novel Hierarchy of Clonal Advantage By Combining Germline and Somatic Mutations. *Blood*, **2016**, 128, 957-957^{2,2}
- 7 Hospital readmission rate for febrile neutropenia (FN) following high dose cytarabine (HiDAC) consolidation chemotherapy for acute myeloid leukemia (AML).. *Journal of Clinical Oncology*, **2017**, 35, e18513-e18513 2.2
- 6 A Proof of Principle Clinical Trial in Myelodysplastic Syndromes of Non-Cytotoxic Differentiation Therapy with Decitabine,. *Blood*, **2011**, 118, 3830-3830 2.2
- 5 Etiology and treatment of hematological neoplasms: stochastic mathematical models. *Advances in Experimental Medicine and Biology*, **2014**, 844, 317-46 3.6
- 4 Parameter perturbations in a post-treatment chronic myeloid leukemia model capture the essence of pre-diagnosis A-bomb survivor mysteries. *Radiation and Environmental Biophysics*, **2021**, 60, 41-47 2
- 3 Risk of hematologic malignancies after breast ductal carcinoma in situ treatment with ionizing radiation. *Npj Breast Cancer*, **2021**, 7, 21 7.8
- 2 Recent data obtained by pulsed-field gel electrophoresis suggest two types of double-strand breaks. *Radiation Research*, **1998**, 149, 52-8 3.1
- 1 Misrejoining of double-strand breaks after X irradiation: relating moderate to very high doses by a Markov model. *Radiation Research*, **1998**, 149, 59-67 3.1